

I. AMENDMENT

In the Claims:

The following listing of claims will replace all prior versions and listings of the claims in the application:

Listing of the Claims:

1. (currently amended) A pharmaceutical gel comprising:

a solvent vehicle comprising 25 to 100 parts by weight water or buffered water and 0 to 75 parts by weight of ethanol, propylene glycol, glycerin, polyethylene glycol, or combinations thereof, where the solvent vehicle is 100 parts by weight total;

at least one water-insoluble swellable mucoadhesive polymer, wherein the water-insoluble swellable mucoadhesive polymer is crossed-linked polyacrylic acid ;

at least one pH-sensitive anionic film-forming polymer copolymer of methacrylic acid and methacrylic acid esters, which forms forming a film when applied to skin or a mucosal surface, and

at least one molecule of interest.
2. (canceled).
3. (original) The gel of claim 1, wherein the water-insoluble swellable mucoadhesive polymer is polyacrylic acid cross-linked with polyalkenyl ether or divinyl glycol.
4. (previously presented) The gel of claim 1, wherein the water-insoluble swellable mucoadhesive polymer is NOVEON or CARBOMER.
5. (original) The gel of claim 1, wherein the water-insoluble swellable mucoadhesive polymer is present at a concentration of from 0.1% to 20% by weight.
6. (canceled)

7. (original) The gel of claim 1, wherein the pH-sensitive polymer is present at a concentration of from 0.05% to 10% by weight.
8. (previously presented) The gel of claim 1, wherein the pH-sensitive polymer is a EUDRAGIT polymer.
9. (previously presented) The gel of claim 1, wherein the molecule of interest comprises an active pharmaceutical.
10. (original) The gel of claim 1, wherein the molecule of interest is amlexanox.
11. (original) The gel of claim 1, wherein the molecule of interest is triclosan.
12. (original) The gel of claim 1, wherein the molecule of interest is hirudin.
13. (original) The gel of claim 1, wherein the molecule of interest is plasmid DNA.
14. (original) The gel of claim 1, wherein the molecule of interest is lidocaine, benzocaine, or dyclonine.
15. (previously presented) The gel of claim 1, wherein the molecule of interest is at least one benzodiazepine drug.
- 16-26. (canceled).
27. (currently amended) The gel of claim [[16]]1, wherein the molecule of interest is a peptide or protein.
- 28-32. (canceled).
33. (previously presented) The gel of claim 9, wherein the active pharmaceutical comprises an antimicrobial, antiviral, antiinflammatory, antiseptic, antihistamine, a local anesthetic, a disinfectant, a keratolytic, an analgesic, an anti-migraine, an anti-fungal, a sweetener, a flavoring agent, a diagnostic agent, or combination thereof.

34. (canceled)